Aileron Therapeutics Appoints Steven Kafka, Ph.D. as Company`s First Chief Financial Officer and Vice President, Finance and Operations

-Industry Executive Brings Extensive Strategic and Operating Experience to Novel
Therapeutics Company-
CAMBRIDGE, Mass.--(Business Wire)--
Aileron Therapeutics, a biotechnology company discovering and developing a novel
class of therapeutics called Stapled Peptides, announced today that it has
appointed Steven Kafka, Ph.D., as the Company`s first Chief Financial Officer
and Vice President, Finance and Operations. This appointment reflects Aileron`s
growth and expansion as the company creates a pipeline of novel stapled peptide
drugs.

Dr. Kafka will lead Aileron`s strategic and operational finance activities,
direct corporate communications, human resources, and operations and support the
company`s business development effort. He will report to Joseph A. Yanchik III,
Aileron's Chief Executive Officer.

"After securing a significant round of funding earlier this year, Aileron`s
strategic focus is now to drive our lead program into clinical development and
to expand our work on additional targets through partnerships with
pharmaceutical companies," said Joseph Yanchik, III, Chief Executive Officer of
Aileron Therapeutics. "Steve`s deep and broad financial expertise coupled with
his strategic background will be invaluable in helping us achieve these
important milestones."

Dr. Kafka brings more than 12 years of experience in finance, strategic
planning, business development, operations, corporate communications and early
commercial development. Before joining Aileron, Dr. Kafka served as Vice
President, Finance for Infinity Pharmaceuticals (NASD: INFI), where he led
finance, investor and public relations and business operations, and was a key
member of the team that recently secured an alliance with Purdue Pharma and
Mundipharma worth up to $500 million over five years. Previously, Dr. Kafka was
Senior Director, Finance, at Millennium Pharmaceuticals, where as an inaugural
member of the VELCADE® product team he drove strategic planning and alliance
management efforts with partner Johnson & Johnson for this novel cancer therapy
that today generates more than $1 billion in revenue worldwide. Earlier, Steve
was a senior engagement manager with Strategic Decisions Group, providing
product and portfolio strategy consulting to large pharmaceutical companies. Dr.
Kafka earned his Ph.D. from Harvard University and his B.A. with Distinction and
Honors from Stanford University.

"Joining Aileron is a rare opportunity to be at the hub of building what I
believe will be a transformative technology," said Dr. Kafka. "There is enormous
potential for our Stapled Peptide product platform to open a new therapeutic
frontier. Aileron is uniquely poised to advance a completely novel class of
drugs, creating meaningful new medicines for patients and value for our
investors."

About Aileron Therapeutics

Aileron Therapeutics is a biopharmaceutical company that was first funded in
2005 by Apple Tree Partners to develop and advance a completely new therapeutic
modality and class of drugs called Stapled Peptides that are based on
discoveries made at Harvard University and the Dana-Farber Cancer Institute.
Stapled Peptide drugs represent the first general solution for modulating
protein-protein interactions, which have been identified as critical control
points for most human diseases. As such, Stapled Peptide drugs offer a unique
opportunity to exploit potentially thousands of currently "undruggable" targets
across all human diseases. Aileron is building a robust pipeline of therapeutics
for the treatment of cancer, infectious disease, metabolic disease and
immune/inflammatory diseases. Aileron Therapeutics is based in Cambridge,
Massachusetts. For additional information, please visit www.aileronrx.com.

Yates Public Relations
Kathryn Morris, 845-635-9828

Copyright Business Wire 2009